Bionomics Invites Shareholders to Vote on Important Changes
Bionomics Limited (NASDAQ: BNOX), a clinical-stage biotechnology firm known for developing allosteric ion channel modulators, is calling on its shareholders to cast their votes concerning a pivotal Scheme Implementation Agreement. This agreement aims to transition Bionomics from its current base in Australia to a more advantageous positioning in the United States.
Strategic Importance of Re-Domiciliation
According to Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, this re-domiciliation is crucial for the company’s strategic growth. He emphasized that the Board of Directors, alongside an independent expert, unanimously believes that this move serves the best interests of the shareholders:
“The re-domiciliation of Bionomics through the Scheme is key for our ability to execute our strategic vision and set the Company for success,” Dr. Papapetropoulos stated.
Voting Details and Importance
Shareholders are encouraged to participate actively, with voting open until significant deadlines. Dr. Papapetropoulos expressed gratitude towards those who have already voted and urged others to do so before the Proxy cut-off time. The deadline for holders of American Depositary Shares is set for 10:00 am New York time, while holders of ordinary shares must vote by 8:30 am Sydney time.
Comprehensive Voting Information
In preparation for casting their votes, Bionomics shareholders are advised to thoroughly review the Scheme Booklet. This document provides critical insights that will inform their voting decisions regarding the Scheme. An upcoming Scheme Meeting will host discussions on the transition, taking place online to accommodate participants globally.
Online Meeting Participation
For those interested in attending the Scheme Meeting, it will occur at 8:30 am Sydney time on Thursday, with corresponding timings in New York noted for clarity. The meeting will be accessible via an online platform designed to facilitate smooth interactions among all attendees, enhancing shareholder engagement.
Bionomics’ Innovative Approach to CNS Disorders
As innovative biotechnology advances, Bionomics continues to lead in developing novel therapies for serious central nervous system (CNS) disorders. Their flagship drug candidate, BNC210, aims at treating social anxiety disorder and provides insights into the company's vision of addressing high unmet medical needs effectively.
Collaborations and Future Potential
In addition to its current drug pipeline, Bionomics has forged a partnership with Merck & Co., which supports two ongoing clinical trials targeting cognitive deficits related to Alzheimer’s disease. This collaborative effort further solidifies Bionomics’ commitment to advancing CNS treatment options.
Contact Information for Investors
For inquiries regarding shareholder opportunities or further information on the re-domiciliation process, Bionomics provides multiple channels for communication. Rajeev Chandra, the Company Secretary, can be contacted for general queries, while dedicated Investor Relations representatives Kevin Gardner and Chris Calabrese are available as well.
Frequently Asked Questions
Why is Bionomics re-domiciling from Australia to the U.S.?
The re-domiciliation aims to position Bionomics better for growth and strategic execution by aligning closer with significant markets and stakeholders in the U.S.
What should shareholders read before voting?
Shareholders are advised to read the Scheme Booklet detailedly, which outlines critical information that impacts their voting decision.
When will the Scheme Meeting take place?
The Scheme Meeting is scheduled for 8:30 am Sydney time, and timings are provisioned for New York participants as well.
Who can I contact for more information?
Investors seeking more details can reach out to Bionomics’ Company Secretary or Investor Relations representatives via the contact information provided in the announcement.
What is the benefit of Bionomics' drug candidate BNC210?
BNC210 targets social anxiety disorder and is a significant part of Bionomics' strategy to address critical CNS disorder needs, showcasing the company’s innovative approach in the biotech sector.
